What are pharmaceutical intermediates? Development trend of pharmaceutical intermediates
Pharmaceutical intermediates, as some chemical raw materials or chemical products in the process of pharmaceutical production synthesis, have always been essential products in the pharmaceutical industry. Choosing a reliable and reliable manufacturer is the guarantee for pharmaceutical manufacturers to produce drugs. Zhuoding Biology focuses on the production and sales of pharmaceutical intermediates, the integration of research and production, and the short development and delivery period. It has a massive process database to meet the needs of niche and multi-batch development.
Industry status analysis
After the brilliance of the late 1990s, the pharmaceutical intermediates industry has basically entered the mature stage of competition between enterprises has reached a white heat, each other are fighting for the rest of the power who can adhere to, who is the survivor. At the same time, lured by various legends and other factors, new investors continue to enter the industry full of "gold rush" dreams. However, with the rise of GMP certification and various overseas certifications required by the state, the scale of investment in the pharmaceutical industry has increased exponentially. How to make the limited funds and energy produce economic and social benefits has become the goal pursued by every pharmaceutical intermediate investor.
The trail goes from medicine to medicine
The impact of the process of economic globalization on our economy is more profound than its concept, that is, each production enterprise does not need to be big and full, and should focus its capital and energy on the industry and field it is good at. Other supporting materials and conditions can be completed by social cooperation, through the formation of a product chain to cooperate, the two sides to achieve a win-win situation under the influence of this concept, the pharmaceutical industry will some primary product processing such as solvent recovery and other work transferred to the collaborative enterprises to complete. Later, some products with certain pollution and danger were gradually transferred to chemical plants for production, such as phenylacetic acid chloroacetic acid used in the production of penicillin. In the vicinity of Shijiazhuang, a large number of small township enterprises and individual enterprises supporting the production of phenylacetic acid and chloroacetic acid for North China pharmaceutical have appeared since the 1970s and 1980s.
With the deepening of cooperation between the two sides, pharmaceutical companies gradually transfer some products with higher added value and greater technical difficulty to chemical plants. Production such as the production of cephalosporin antibiotics used in aminotaxime acid AE-active ester triazine cyclotetrazolazolacetic acid p-hydroxyphenylglycine (Deng potassium salt) HO-EPCP and other products, which makes the branch industry in the 1990s has been rapid development and achieved a number of pharmaceutical intermediates with an output value of tens of millions to hundreds of millions of yuan. At present, the industry has developed to the stage of closer cooperation with pharmaceutical companies. The manufacturers of pharmaceutical intermediates directly synthesize the apis (bacteria powder), and sell the products in the form of chemical products to pharmaceutical companies for refining. The pharmaceutical intermediates industry can further extend the product chain, increase the profit of the product and improve the stability of sales, while pharmaceutical companies reduce investment and focus their limited capital and energy on the aseptic packaging they are good at. Without the production license of pharmaceutical products, it is impossible to compete for the market with pharmaceutical companies, so the cooperation between the two sides is complementary to a certain extent.
Basic conditions are still constraining development
In recent years, the rapid development of the pharmaceutical intermediates industry has caused many investors to salivate that companies producing pharmaceutical intermediates apis have sprung up all over the country. But at the same time, it is eliminated at a similar speed, many technical personnel engaged in the development of pharmaceutical intermediates products have also been involved in the industry in various forms, but with the collapse of the corresponding enterprises have also returned to the development of the industry seems to be like the ebb and flow of many losers with the hurried back of the author as one of the many losers. After a leisurely reflection, I think that the reason why many people and financial resources involved in the industry are so "come and go" is not that the industry has reached a new bottleneck, but mainly because it is basically but often forgotten by many "gold diggers".
You have the money and you have the technology to produce the product. However, only those who sell the products and recover the funds in time can reproduce them. Due to the close relationship between the pharmaceutical intermediates industry and the pharmaceutical industry, the sale of products is also very delicate. The competition between suppliers has been transformed into the competition of comprehensive strength among enterprises. Intuitive factory appearance Factory appearance Production workshop and laboratory equipment product packaging and quality Intangible including technical strength after-sales service corporate culture business philosophy, so the comprehensive market background is also one of the indispensable conditions.